Welcome to our dedicated page for The Oncology Institute Warrant news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute Warrant stock.
The Oncology Institute, Inc. provides value-based community oncology care through clinics and affiliate locations across multiple states. Company updates commonly cover quarterly results, payor and Medicare Advantage contract activity, capitated care models, specialty pharmacy performance, clinical trials, transfusions, and participation in CMS oncology care programs.
News also addresses clinical pathways, legal and compliance leadership, and healthcare investor conference participation. The issuer's public securities include common stock under TOI and redeemable warrants under TOIIW.
The Oncology Institute (NASDAQ: TOI), one of the largest value-based oncology groups in the US, announced significant leadership changes to its Board of Directors. Richard Barasch will retire as Chairman of the Board, effective August 12, 2025, with Anne McGeorge, current Board Member and Audit Committee Chair, succeeding him.
McGeorge brings over 35 years of healthcare experience, notably having grown Grant Thornton LLP's Global Health Care and Life Sciences Practice into a $250 million global business. She currently serves on multiple boards including Dianthus Therapeutics (NASDAQ: DNTH), Nimbus Therapeutics, and CitiusTech.
Under Barasch's leadership, TOI successfully became a publicly traded company and expanded its business model beyond California.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025, after market close.
The company will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or webcast through TOI's Investor Relations website. A replay will be available until August 20, 2025, using passcode 13754165.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has appointed Kristin England as its new Chief Administrative Officer (CAO), effective July 7, 2025. In this newly created position, England will be responsible for overseeing Enterprise Central Business Operations and Technology Strategy across TOI's national operations.
England joins TOI with over 20 years of healthcare management experience, previously serving as a senior executive at McKesson's US Oncology Network, where she specialized in revenue cycle optimization and practice management systems improvement. CEO Daniel Virnich emphasized that England's appointment comes at a crucial time as TOI focuses on scaling its MSO model and strengthening its value-based care approach.
The Oncology Institute (NASDAQ: TOI) has announced a significant partnership with SilverSummit Healthplan, becoming the exclusive oncology provider for over 80,000 Medicaid patients in Nevada, effective July 1. This expansion marks an important step in TOI's mission to provide value-based cancer care to underserved communities.
The partnership will operate through three Nevada locations in Las Vegas, Henderson, and Spring Valley, offering comprehensive cancer care services to SilverSummit Healthplan members. This collaboration aligns with TOI's track record of serving Medicaid patients and SilverSummit's commitment to providing high-quality healthcare access to its members.
The Oncology Institute (NASDAQ: TOI) has appointed Dr. Jeffrey Langsam as its new enterprise Chief Clinical Officer (CCO), effective May 13th, 2025. In this role, Dr. Langsam will oversee therapeutics, including pathway and procurement decisions, utilization management, and MSO practice clinical engagement.
Dr. Langsam joins TOI from Cigna Healthcare, where he served as National Director of Oncology and Senior Medical Director in the Specialty Pharmacy Division. His previous experience includes roles as Regional Medical Director at Aetna and clinical faculty at the University of Connecticut, where he practiced as an oncologist.
The appointment comes as TOI experiences acceleration in new value-based partnerships and growth in its MSO model across the country.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, announced its participation in the upcoming B. Riley's 25th Annual Institutional Investor Conference. The event will take place on May 21st, 2025, in Marina Del Rey, CA. The company will be represented by CEO Dr. Daniel Virnich and CFO Rob Carter.
The Oncology Institute (NASDAQ: TOI) has been selected to present significant findings at the upcoming ASCO Annual Meeting regarding their High-Value Cancer Care (HVCC) model. The study demonstrates remarkable improvements in patient care and cost efficiency:
Key outcomes include:
- 53% reduction in Emergency Department use
- 68% decrease in hospitalizations
- 75% lower odds of acute care facility death
- $12,000 cost savings per enrolled patient
According to TOI's Chief Medical Officer, Dr. Yale Podnos, these results validate their coordinated care approach in delivering superior clinical outcomes while significantly reducing costs for patients and payor partners.
The Oncology Institute (TOI), a leading value-based oncology group in the United States, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on Wednesday, May 14, 2025, followed by a conference call at 5:00 p.m. Eastern Time.
Investors can access the conference call via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or through a simultaneous webcast on TOI's Investor Relations website. A replay will be available for one week until May 21, 2025, using passcode 13752832.